Corporate Briefs On Chemex, Interneuron
- Interneuron Inc of Lexington, Massachusetts says it has acquired all the remaining shares of CPEC Inc not held by its majority-owned subsidiary Intercardia. Intercardia is developing bucindolol, a drug to treat congestive cardiac failure. The purchase price of this remaining 20% stake in CPEC is around 343,000 shares of Interneuron common stock.
- Tarrytown, New York-based Chemex Pharmaceuticals Inc's shareholders have approved a deal, now closed, for a merger with ACCESS Pharmaceuticals of Dallas, Texas. Kerry Gray will be president and chief executive of ACCESS, and Herbert McDade will be chairman. Other directors are Elizabeth Greetham, Michael Flinn and ACCESS founder David Ranney. Chemex, which has been traded on the NY Stock Exchange, has had its name changed to ACCESS, and will continue trading as the latter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze